Anti M, Marra G, Percesepe A, Armelao F, Gasbarrini G
Department of Internal Medicine, Catholic University of Rome, Italy.
J Cell Biochem Suppl. 1994;19:68-75.
The use of biomarkers to assess cancer risk is based on the model of cancer as a multistep process; such markers are assumed to reflect an early stage in this process. A valid biomarker of risk must therefore show differential expression in normal and high-risk subjects, as well as quantitative correlation with the stage of carcinogenesis. It should also be easy to detect in small tissue specimens and responsive to modulation by chemopreventive agents. Cell proliferation is one of the most widely investigated markers of cancer risk. Case-control studies have shown that epithelial cell proliferation parameters, assessed in rectal mucosal biopsies by means of in vitro autoradiographic or immunohistochemical techniques, can discriminate between populations with normal and high risks for colon cancer. However, we recently reviewed rectal biopsies from 152 subjects (43 controls, 84 with adenomas, 25 resected for colon cancer) processed for in vitro 3H-thymidine autoradiography, and attempted to correlate various proliferative parameters with clinical and pathological variables by means of multiple regression analysis. Elevations of total crypt labeling indices (LIs), particularly upper crypt LIs, were significantly associated with the presence of adenomatous polyps, although subsequent linear discriminant analysis revealed that the accuracy of LIs in discriminating between polyp patients and controls was actually quite low. However, we have also found that upper crypt LIs are reliable predictors of adenomatous polyp recurrence. Repeated evaluations of rectal proliferative indices over a 2-year post-polypectomy follow-up of 40 patients with colonic adenomas revealed substantial stability.(ABSTRACT TRUNCATED AT 250 WORDS)
使用生物标志物评估癌症风险是基于癌症为多步骤过程的模型;此类标志物被认为反映了该过程的早期阶段。因此,一个有效的风险生物标志物必须在正常和高危人群中表现出差异表达,并且与致癌作用阶段存在定量相关性。它还应易于在小组织标本中检测到,并对化学预防剂的调节有反应。细胞增殖是研究最广泛的癌症风险标志物之一。病例对照研究表明,通过体外放射自显影或免疫组化技术在直肠黏膜活检中评估的上皮细胞增殖参数,可以区分患结肠癌风险正常和高危的人群。然而,我们最近回顾了152名受试者(43名对照、84名患有腺瘤、25名因结肠癌接受切除)的直肠活检标本,这些标本经过体外3H-胸腺嘧啶核苷放射自显影处理,并试图通过多元回归分析将各种增殖参数与临床和病理变量相关联。总的隐窝标记指数(LIs)升高,尤其是上部隐窝LIs,与腺瘤性息肉的存在显著相关,尽管随后的线性判别分析显示,LIs区分息肉患者和对照的准确性实际上相当低。然而,我们还发现上部隐窝LIs是腺瘤性息肉复发的可靠预测指标。对40名结肠腺瘤患者息肉切除术后2年的随访中对直肠增殖指数的重复评估显示出相当的稳定性。(摘要截短于250字)